Clinical analysis of sentinel lymph node biopsy in 80 breast cancer cases

Abstract

Abstract: AIM: To investigate the application and clinical efficiency of sentinel lymph node biopsy (SLNB) in breast cancer.METHODS: The sentinel lymph nodes (SLNs) of 80 patients with breast cancer were detected by SLNB with intraoperative frozen section and methylene blue staining.The results were compared with serial section and immunohistochemical staining of SLN after operation.RESULTS: 69 of 80 patients were successfully detected by SLNB, with achievement ratio of 86.3%.24 patients were found positive of carcinomatous metastasis by intraoperative frozen section and methylene blue staining, while 45 negative patients were examined by serial section and immunohistochemical staining after operation and found 5 cases with micrometastasis.CONCLUSION: SLNB with methylene blue staining was safe, cheap and had high achievement ratio.The status of SLNs had important prefigurative value about axillary lymph nodes in breast cancer.The application of serial section associated with immunohistochemical staining of SLN could increase the detective rate of metastasis, and reduce the false negative rate.

Key words: breast cancer, sentinel lymph node, micrometastasis

CLC Number:

R737.9

CHEN Xian-jun, WANG Ya-bing, HONG Shu-jian, WU Jian, XU Guo-qiang, ZHANG Fan. Clinical analysis of sentinel lymph node biopsy in 80 breast cancer cases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 654-656.

References

[1] 刘国津, 范志民, 唐强, 等. 乳腺癌前哨淋巴结定位和活检[J]. 中国肿瘤临床, 2000, 27(7): 485-487.
[2] Weaver DL, Ashikaga T, Harlovo SP, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma[J]. Cancer, 2000, 88(5): 1099-1107.
[3] Nason KS, Anderson BO, Donohue JH, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma[J]. Cancer, 2000, 89(1): 2187-2194.
[4] 李林, 谷元廷, 僧靖静, 等. 染料法乳腺癌前哨淋巴结活检的临床应用[J]. 中华肿瘤防治杂志, 2007, 14 (9): 709-711.
[5] 陈理达, 赵挺, 胡晓清, 等. 87 例早期乳腺癌术中前哨淋巴结活检应用分析[J]. 中国肿瘤, 2007, 16(5): 380-381.
[6] 刘君, 方志沂, 于泳, 等. 乳腺癌前哨淋巴结微转移检测在根治术中的应用[J]. 中国肿瘤临床, 2001, 28 (8): 576-578.
[7] McMasters KM, Giuliano AE, Ross MI, et al. Sentinel lymph node biopsy for breast cancer-not yet the standard of care[J]. N Engl J Med, 1998, 339(4): 990.
[8] 何建军, 任予, 乔广东, 等. CK19 检测乳腺癌前哨淋巴结微转移的价值[J]. 中国现代医学杂志, 2002, 12(2): 16-18.
[9] Liu LH, Siziopikou KP, Gabram S, et al. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel section in patients with breast cancer [J]. Arch Pathol LabMed, 2000, 124(11): 1670-1673.
[10] 邬一军, 周新惠, 黄钟英, 等. 乳腺癌前哨淋巴结定位及其微转移检测的研究[J]. 中华外科杂志, 2001, 39(9): 733.
[11] Roumen RM, Kuijt GP, Liem IH, et al. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection[J]. Br J Surg, 2001, 88(12): 1639-1643.
[12] 王永胜, 王磊, 刘娟娟, 等. 临床早期乳腺癌前哨淋巴结活检替代腋清扫术的研究[J]. 实用临床医药杂志, 2003, 7(2): 99-103.
[13] Lyman G, Giuliano AE, SomerfieldMR, et al. American Society of Clinical Oncology guiedeline recommendations for sentinel lymph node biopsy in early-stage breast cancer [J]. J Clin Oncol, 2005, 23(30): 7703-7720.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[4]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[5]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[6]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[7]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[8]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[9]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[10]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
[11]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[12]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[13]	XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi. Population pharmacokinetics of capecitabine in Chinese breast cancer patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
[14]	SUN Hong, HOU Jialin, CAI Jiaqin, WEI Xiaoxia, ZHUANG Jie. SUMO E3 ligase mediates androgen receptor transcription to promote tamoxifen resistance of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 285-291.
[15]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.